𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma : Results of Eastern Cooperative Oncology Group study E2479

✍ Scribed by Martin M. Oken; David P. Harrington; Neil Abramson; Robert A. Kyle; William Knospe; John H. Glick

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
97 KB
Volume
79
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

METHODS.

Four hundred seventy-nine previously untreated patients with multiple myeloma from 23 ECOG institutions were enrolled. Treatment, assigned by ran-1 The Virginia Piper Cancer Institute and the Unidomization, consisted of either 4-week cycles of MP or 5-week cycles of VBCMP.

πŸ“œ SIMILAR VOLUMES

The use of low-dose prednisone and melph
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma
✍ Cuttner, Janet ;Wasserman, L. R. ;Martz, Georg ;Sonntag, Roland W. ;Kyle, Robert πŸ“‚ Article πŸ“… 1975 πŸ› John Wiley and Sons 🌐 English βš– 416 KB

## Abstract A study was designed to evaluate the effectiveness of prednisone therapy in poor‐risk patients with multiple myeloma. Patients were treated with melphalan alone or in combination with prednisone at doses of either 0.6 mg/kg or 0.3 mg/ kg. The group of patients receiving melphalan and pr

Cyclophosphamide plus dexamethasone is a
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

Randomized trial of initial therapy with
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term resultsβ€”Eastern Cooperative Oncology Group study E2878
✍ Scott Wadler; Beow Yeap; Steven Vogl; Paul Carbone πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 781 KB

## BACKGROUND. Following surgical debulking, most patients with International Federation of Gynecology and Obstetrics (FIGO) Stage 111 or IV carcinoma of the ovary receive treatment with combination chemotherapy. However, the optimal postsurgical therapy for ovarian carcinoma remains to be defined

The addition of interferon or high dose
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486
✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera